Cohen Veterans Network Unveils New Awareness Campaign, 'PTSD: What Therapists Want You to Know'
'Why can two people respond differently to the same trauma?' New video series answers common questions with insights from mental health experts who specialize in treating PTSD
STAMFORD, Conn., June 11, 2025 /PRNewswire/ -- This June, coinciding with PTSD Awareness Month, Cohen Veterans Network (CVN), a national not-for-profit network of mental health clinics for post-9/11 veterans, service members, and their families, is launching a new public awareness campaign, "PTSD: What Therapists Want You to Know." The initiative features a video series with key insights from mental health experts who specialize in treating trauma and PTSD. The campaign aims to challenge misconceptions about the disorder and underscore that effective treatments are available.
Posttraumatic Stress Disorder (PTSD) is a mental health disorder that some people develop after experiencing or witnessing a life-threatening event, like combat, a natural disaster, a car accident, or sexual assault. The U.S. Department of Veterans Affairs reports that at some point in their life, seven out of every 100 veterans (7%) will have PTSD. This rate is similar to that of the U.S. population in which six of every 100 adults (6%) will have PTSD in their lifetime. Currently, there are about 12 million people in the U.S. with PTSD.
"PTSD is often misunderstood, leading to stigma and misinformation that can prevent people from seeking help," said Dr. Anthony Hassan, president and CEO of Cohen Veterans Network. "By increasing awareness and understanding about the disorder, we hope to empower more individuals to take that first step toward care. PTSD is treatable, recovery is possible, and support is available."
The campaign features a series of short, informative videos with information and advice from therapists who work with PTSD every day. The videos address common questions and misconceptions, exploring topics such as why two people can respond differently to the same trauma, what causes PTSD, how to make the most out of trauma treatment, and the importance of using the term "PTSD" accurately. The campaign additionally features an article on Explaining PTSD to Kids: Four Steps for Parents, which provides strategies to help caregivers talk with children about PTSD in the home.
Since 2016, CVN has cared for over 85,000 clients and provided more than 770,000 clinical sessions. Approximately 21% of the network's veteran and active duty clients have received treatment for PTSD. The network additionally treats a wide variety of mental health concerns including depression, anxiety, military transition challenges, adjustment issues, anger, grief and loss, family issues, relationship challenges, and children's behavioral problems. Care is available through the network's 22 Cohen Clinics serving 20 states
in-person and via CVN Telehealth, face-to-face video therapy.
For more information on "PTSD What Therapists Want You to Know" or to access the campaign video series and resources, visit cohenveteransnetwork.org/ptsd.
Cohen Clinic b-roll is available here.
ABOUT COHEN VETERANS NETWORK
Cohen Veterans Network (CVN) is a 501(c)(3) national not-for-profit philanthropic organization for post- 9/11 veterans, active duty service members and their families. CVN focuses on improving mental health outcomes, operating a network of outpatient mental health clinics in high-need communities, in which trained clinicians deliver holistic evidence-based care to treat mental health conditions. It was established in 2016 by philanthropist Steven A. Cohen with a commitment of $275 million to build the network. Learn more about CVN at cohenveteransnetwork.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cohen-veterans-network-unveils-new-awareness-campaign-ptsd-what-therapists-want-you-to-know-302478999.html
SOURCE Cohen Veterans Network
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment. The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia. Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease. About Merry Life Biomedical Company Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs. Media ContactDr. Ih-Jen SuMerry Life Biomedical Company, +886-910-902-296Email: suihjen0704@ View original content to download multimedia: SOURCE Merry Life Biomedical Company, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Taiwan Goes All-In for BIO in Boston: 2025's Pavilion Promotes Biotech Innovation, Tech Power, and Global Partnerships
BOSTON, June 11, 2025 /PRNewswire/ -- Taiwan's delegation, led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), organized by the Ministry of Economic Affairs, and supported by various government agencies, will attend the BIO International Convention 2025, taking place June 16–19 in Boston. The Taiwan Pavilion, themed "Taiwan, Your Best Partner in Asia," brings together 35 companies, one industry association, and six research institutes to showcase advancements in AI-driven healthcare, biomanufacturing, and precision medicine. Building on BIO 2024's success with 19,608 attendees and 61,508 business matchmaking meetings, Taiwan aims to strengthen its role as a global biotech leader by highlighting innovations and expanding international partnerships. The Taiwan Pavilion highlights "Full-Age Precision Medicine," showcasing over 50 technologies addressing healthcare needs across all life stages. Key innovations - Taiwan's expertise in AI enhances medical informatics and smart healthcare solutions, while its biomanufacturing supports global pharmaceutical production. These advancements position Taiwan as a leader in regenerative medicine, medical devices, and contract development and manufacturing organizations (CDMOs). Adding further momentum to Taiwan's presence at the convention, two Taiwanese biotech startups — AnHorn Medicines and Pharmasaga Company Limited — have been selected as finalists in the Start-Up Stadium, a global competition that drew 57 teams from around the world. Their selection reflects the rising profile and competitiveness of Taiwan's biotech sector and provides finalists with a valuable opportunity to engage with global pharmaceutical leaders and venture capitalists, potentially leading to strategic partnerships and funding opportunities. Taiwan's BIO 2025 Key Events to Attend – Tuesday, June 17 Global Innovation Hub – Taiwan (3:15–3:30 p.m., Meeting Room 152):A focused session spotlighting Taiwan's biomedical breakthroughs and collaboration opportunities, reflecting the broad coalition behind Taiwan's delegation across industry, government, academia, and clinical sectors. Taiwan Pavilion Networking Event (4:00–5:00 p.m., Booths 1545 & 1645):An open networking event welcoming global biotech leaders, featuring a Happy Hour and showcasing next-generation technologies, promising products, and emerging opportunities for cross-border collaboration. The Taiwan Pavilion at BIO 2025 (Booth No. 1545 & 1645) showcases numerous biotech companies. Coordinated by BPIPO, it promotes global partnerships in biotech, CDMO, and precision health. Exhibited technologies include cell and gene therapy, novel drug development, smart medical devices, and integrated solutions for all stages of healthcare. As BIO 2025 approaches, Taiwan's delegation prepares to showcase its biotech strengths and global strategy to shape the industry's future. More details and delegation links are available at or by contacting BPIPO. View original content to download multimedia: SOURCE The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below: Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)Abstract #:306-OR Presentation Form: Oral presentationTime: 2025 June 23, 14:15 PM – 14:30 PM(CST)Presenter: Dr. Lei Qian, Innovent Biologics Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract #:1886-LBPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Dr. Decheng Ren, Innovent Biologics Title: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat AccumulationAbstract #:777-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Hong, Peking University Third Hospital Title: Effect of Mazdutide on MASH Fibrosis – Targeting the Liver-Gut Axis and MicrobiomeAbstract #:1616-P Presentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Professor Ling Li, Zhongda Hospital Affiliated to Southeast University Title: Mazdutide, a Dual GLP-1R/GCGRR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine MetabolismAbstract #:775-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Professor Hongwei Jiang, The First Affiliated Hospital of Henan University of Science and Technology Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, "We are honored to orally present the results of mazdutide's first Phase 3 clinical trial in T2D (DREAMS-1) at the ADA Scientific Sessions. We are also delighted to see mazdutide's mechanism exploration studies featured extensively at the conference. The growing body of medical evidence will further validate mazdutide's differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, in particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies, including IBI3030(PCSK9-GGG)with novel modality and MoA, to meaningfully improve outcomes for more patients worldwide." About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Currently, Mazdutide has two NDAs accepted for review by NMPA, including: Long-term weight management in adults with obesity or overweight. Glycemic control in adults with type 2 diabetes (T2D). Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese participants with T2D. DREAMS-2: A Phase 3 trial comparing Mazdutide and Dulaglutide in Chinese T2D participants with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with T2D and obesity. Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and others are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data